Related Experiment Videos
Dexamethasone suppression test in schizophrenia. A study and review
Neuropsychobiology
|January 1, 1986
Summary
Major depressive disorder patients showed a higher prevalence of abnormal dexamethasone suppression test (DST) responses (52.5%) compared to schizophrenic patients (23.5%) and healthy controls (6.7%). This study highlights differences in DST nonsuppression rates across these groups.
Area of Science:
- Neuroscience
- Psychiatry
- Endocrinology
Background:
- The dexamethasone suppression test (DST) is a neuroendocrine test used to assess hypothalamic-pituitary-adrenal (HPA) axis function.
- Abnormal DST responses have been reported in various psychiatric disorders, including major depressive disorder (MDD) and schizophrenia.
- Variability in DST nonsuppression rates in schizophrenia necessitates further investigation into influencing factors.
Purpose of the Study:
- To determine the prevalence of abnormal DST responses in inpatients with major depressive disorder (MDD) and schizophrenia.
- To compare DST nonsuppression rates between MDD patients, schizophrenic patients, and normal controls.
- To review and discuss factors contributing to the wide variability of DST prevalence in schizophrenia.
Main Methods:
- The 1 mg dexamethasone suppression test (DST) was administered to 40 inpatients with MDD, 17 inpatients with schizophrenia, and 30 normal controls.
- DST nonsuppression was defined as a post-dexamethasone serum cortisol level above a specified threshold.
- Prevalence rates were calculated for each group.
Main Results:
- The prevalence of DST nonsuppression was 52.5% in MDD patients, 23.5% in schizophrenic patients, and 6.7% in normal controls.
- A significantly higher rate of DST nonsuppression was observed in MDD patients compared to both schizophrenic patients and normal controls.
- The prevalence of DST nonsuppression in schizophrenics was within the reported range from previous literature.
Conclusions:
- Major depressive disorder is associated with a high prevalence of abnormal DST responses, suggesting significant HPA axis dysregulation.
- While DST nonsuppression is observed in schizophrenia, the prevalence is lower than in MDD and shows considerable variability in the literature.
- Factors such as comorbid depression, dexamethasone dosage, and inpatient status may influence DST results and contribute to prevalence discrepancies across studies.